期刊
JOURNAL OF CLINICAL MEDICINE
卷 11, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/jcm11102856
关键词
bullous pemphigoid; immunology; therapeutic target; randomized controlled trials
资金
- Department of Veterans Affairs (VA Merit Review: VA-ORD) [5 I01 BX000706]
This article summarizes the pathogenesis and treatment options for bullous pemphigoid (BP). BP primarily affects the elderly and long-term use of corticosteroids and immunosuppressants can cause significant side effects. Therefore, developing effective and side-effect-free treatment options is crucial. The review focuses on the role of eosinophils, immunoglobulins, cytokines, and complements in the development of BP, and discusses the latest advances in novel therapeutic targets. Access to medication for refractory patients is also an important consideration.
Bullous pemphigoid (BP) is a rare, chronic antibody-mediated autoimmune blistering disease primarily affecting the elderly, with an age of onset over 60. Current treatment options are limited and involve the use of corticosteroids and immunosuppressants, but their long-term use is associated with significant morbidity and mortality. In Japan, human intravenous immunoglobin is approved for the treatment of corticosteroid-refractory BP. However, no treatment option is approved by the Food and Drug Administration for the management of BP. Therefore, developing effective therapies free of debilitating side effects is imperative. In this review, we summarize the main immunologic pathways involved in the pathogenesis of BP, with an emphasis on the role of eosinophils, immunoglobulins, cytokines such as the interleukin (IL)-4 and IL-5, and complements. We further discuss the latest advances with novel therapeutic targets tested for the management of BP. Ongoing efforts are needed to run well-designed controlled trials and test the efficacy and safety of investigational drugs while providing much-needed access to these medications for refractory patients who will not otherwise be able to afford them as off-label prescriptions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据